Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Global trends in clinical studies of ivermectin in COVID-19

Yagisawa et al., The Japanese Journal of Antibiotics, 74-1, Mar 2021
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now known with p < 0.00000000001 from 103 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,200+ studies for 60+ treatments. c19ivm.org
Review of ivermectin for COVID-19. Authors note that Kitasato University's project was expanded in response to the results of Caly et al. which had left questions regarding in vivo therapeutic levels, and the results of those studies were positive. Early in the pandemic, Kitasato University requested Merck to conduct clinical trials in Japan because they have priority for an expansion of ivermectin's indications, however Merck declined.
Since large companies have declined to study ivermectin for COVID-19, trials have been mostly doctor-initiated with relatively little funding. Authors discuss these, noting that the physicians involved are enthusiastic about avoiding bias, and strive to treat and prevent COVID-19 witn non-profit motives.
Authors discuss the trials, epidemiological data, and inaccurate statements made by certain authorities.
Authors note that regulations make it challenging for doctor-initiated trials to enroll many participants in a timely manner.
Authors conclude that ivermectin may turn out to be comparable to the benefits achieved from the discovery of penicillin - said to be one of the greatest discoveries of the twentieth century.
Authors include the nobel prize winning biochemist who discovered ivermectin, Satoshi Ōmura en.wikipedia.org.
Yagisawa et al., 24 Mar 2021, peer-reviewed, 4 authors.
This PaperIvermectinAll
Global trends in clinical studies of ivermectin in COVID-19
Ph.D Morimasa Yagisawa, M.D Patrick J Foster, Ph.D Hideaki Hanaki, Ph.D Satoshi Ōmura
Response to the initial alarm bells of the Coronavirus infection, which occurred in Wuhan City, Hubei Province, China in November 2019, was delayed as it was announced to be a type of pneumonia of unknown cause. The WHO warned about traveling to China in January 2020. After much urging, the world was finally properly warned, but the Chinese government did not accurately announce the outbreak situation. Consequently, the delaying of the construction of an epidemic prevention system worldwide has resulted in the direst infection circumstances facing the world today. One year has passed since the WHO named the new coronavirus SARS-CoV-2 infection, COVID-19, and it was declared a pandemic on the 11 th of March 2020, based on the judgment that it corresponds to "an internationally concerned public health emergency". Suppression of virus transmission by vaccine has finally begun. To date, the pandemic has affected more than 115 million people and killed more than 2.5 million people in 220 countries/ regions around the world. There appears to a potential for control in the near future. However, there is a limit to the supply of vaccines and developed countries are competing to obtain the required amount of vaccination necessary for their own citizens. Although the WHO is trying to secure a certain amount for developing countries, it is predicted that a considerable period of time will be required before COVID-19 becomes controllable. On the other hand, with regard to therapeutic agents for COVID-19, studies began at an early stage. The therapeutic effects of hydroxychloroquine or chloroquine, lopinavir/ritonavir combination, tocilizumab, interferon β1, as well as others, were found to have limited efficacies or no effect. Remdesivir improves recovery time by as much as 30% in critically ill patients, but it is not suitable for mild to moderately ill patients-which comprises the majority of infected individuals. Although the Mar. 2021 THE JAPANESE JOURNAL OF ANTIBIOTICS 74-1 45 ( 45 ) steroid drug dexamethasone is effective in alleviating inflammatory symptoms, its use in mild to moderately ill patients without significant inflammatory symptoms is not recommended. Currently, there are no therapeutic agents available for mildly ill patients who are being treated at home (or in self-isolating accommodations) or for moderately ill hospitalized patients. Nothing is as helpless as a disease without a cure. In a situation where the number of COVID-19 patients is rapidly expanding, the number of deaths increasing worldwide, hydroxychloroquine, doxycycline, azithromycin, and other drugs are ineffective for therapeutic purposes, an effective treatment method is being sought. An Australian research group reported that ivermectin suppresses SARS-CoV-2 replication in an in vitro infection experiment. Ivermectin has been widely used since 1987 for the control of river blindness and lymphatic filariasis, as well as in the treatment of scabies in humans...
Conflict of Interest None to declare.
References
Ahmed, Karim, Ross, A five day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness, Int J Infect Dis. Pre-print, doi:10.1016/j.ijid.2020.11.191
Alam, Murshed, Bhiuyan, Saber, Alam et al., A case series of 100 COVID-19 positive patients treated with combination of ivermectin and doxycycline, J Bangladesh Coll Phys Surg
Analysis, Ivermectin is effective for COVID-19: real-time meta analysis of 42 studies
Astrazeneca, Co, Ltd, submits application for manufacturing and marketing approval of new coronavirus vaccine in Japan
Authenticated, Government Information. 21st Century Cures Act, Public Law
Babalola, Bode, Ajayi, Ivermectin shows clinical benefits in mild to moderate COVID19: a randomised controlled double-blind dose-response study in Lagos, QJM Int J Med, doi:10.1093/qjmed/hcab035
Beigel, Tomashek, Dodd, Mehta, Zingman et al., Remdesivir for the treatment of Covid-19 -Final report, N Engl J Med
Bernigaud, Guillemot, Ahmed-Belkacem, Oral ivermectin for a scabies outbreak in a long-term-care facility: Potential value in preventing COVID-19 and associated mortality?, Brit J Dermatol. Accepted article, doi:10.1111/bjd.19821
Bhimra, Morgan, Shumaker, Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease
Bhimra, Morgan, Shumaker, Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19), Clin Infect Dis, doi:10.1093/cid/ciaa478
Bryner, 1st known case of coronavirus traced back to November in China, Live Science
Bukhari, Asghar, Perveen, Efficacy of ivermectin in COVID-19 patients with mild to moderate disease, doi:10.1101/2021.02.02.21250840
Cadegiani, Goren, Wambier, Mccoy, Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient setting significantly reduced symptoms compared to known outcomes in untreated patients, doi:10.1101/2020.10.31.20223883
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res, doi:10.1016/j.antiviral.2020.104787
Carvallo, Hirsch, Farinella, Safety and efficacy of the combined use of ivermectin, dexamethasone, exoxaparin and aspirin against COVID-19, doi:10.1101/2020.09.10.20191619
Carvallo, Roberto, Psaltis, Veronica, Study of the efficacy and safety of topical ivermec-tin+iota-carrageenan in the prophylaxis against COVID-19 in health personnel, J Biomed Res Clin Invest, doi:10.31546/2633
Chaccour, Casellas, Blanco-Di Matteo, The effect of early treatment with ivermectin on viral load, symptoms
Chaccour, Hammann, Garcia, Rabinovich, Ivermectin and COVID-19: Keeping rigor in times of urgency, Am J Trop Med Hyg
Chachar, Khan, Asif, Khushbakht, Khaqan et al., Effectiveness of ivermectin in SARS-CoV-2/COVID-19 patients, Int J Sci, doi:10.18483/ijSci.2378
Chamie-Quintero, Hibberd, Scheim, Ivermectin for COVID-19 in Peru: 14-fold reduction in nationwide excess deaths, doi:10.31219/osf.io/9egh4
Chamie-Quintero, Hibberd, Scheim, Sharp reductions in COVID-19 case fatalities and excess deaths in Peru in close time conjunction, state-by-state, with ivermectin treatments
Chowdhury, Shahbaz, Karim, Islam, Guo et al., A randomized trial of ivermectin-doxycycline and hydroxychloroquine-azithromycin therapy on COVID-19 patients, doi:10.21203/rs.3.rs-38896/v1
Crump, Ivermectin: enigmatic multifaced ʻwonderʼ drug continues to surprise and exceed expectations, J Antibiot
Dasgupta, Sen, Bakshi, Nsp7 and spike glycoprotein of SARS-CoV-2 are envisaged as potential targets of vitamin D and ivermectin, Preprints
Dayer, Coronavirus (2019-nCoV) deactivation via spike glycoprotein shielding by old drugs, bioinformatic study
De Melo, Lazarini, Larrous, Anti-COVID-19 efficacy of ivermectin in the golden hamster, doi:10.1101/2020.11
Drozdzal, Rosik, Lechowicz, FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy, Drug Resist Updat, doi:10.1016/j.drup.2020.100719
Elgazzar, Hany, Youssef, Hany, Hafez et al., Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic, Research Square preprint, doi:10.21203/rs.3.rs-100956/v1
Espitia-Hernandez, Munguia, Diaz-Chiguer, Lopez-Elizalde, Jimenez-Ponce, Effects of ivermectin-azithromycin-cholecalciferol combined therapy on COVID-19 infected patients: A proof of concept study, Biomed Res
Flccc Alliance, Dr, Kory, president of the FLCCC Alliancce tells Senate Committee on Homeland Security and Governmental Affairs looking into arly outpatient COVID-19 treatment
Flccc Alliance, FLCCC Alliance response to Merckʼs public statements on ivermectinʼs efficacy in COVID-19
Flccc Alliance, FLCCC Alliance response to the NIH guideline committee recommendation on ivermectin use in COVID-19 dated
Flccc Alliance, NIH revises treatment guidelines for ivermectin for the treatment of COVID-19. Ivermectin is now a therapeutic option for doctors & prescribers
Flccc Alliance, One Page Summary of the Clinical Trials Evidence for Ivermectin in COVID-19
Flccc Alliance, investigators of the Oxford PRINCIPLE Trial on ivermectin in COVID-19
Flvenson, COVID-19: association with rapidly progressive forms of alopecia areata, Int J Dermatol
Fontanet, Autran, Lina, Kieny, Karim et al., SARS-CoV-2 variants and ending the COVID-19 pandemic, Lancet online, doi:10.1016/S0140-6736(21)00370-6
Food, Drug Administration: FDA issues emergency use authorization for convalescent plasma as potential promising COVID-19 treatment, another achievement in administrationʼs fight against pandemic
Gates, Responding to Covid-19 -A once-in-a-century pandemic?, N Eng J Med. online February, doi:10.1056/NEJMp2003762
Gorial, Mashhadani, Sayaly, Effectiveness of ivermectin as add-on therapy in COVID-19 management (Pilot Trial, doi:10.1101/2020.07.07.20145979
Gorial, University, Baghdad, Efficacy of ivermectin as add on therapy in COVID19 patients
Guerrero, Bravo, Munoz, Ardila, Guerrero, COVID-19: The ivermectin African enigma, Colomb Med
Gupta, Sahoo, Singh, Ivermectin: potential candidate for the treatment of Covid-19, Braz Infect Dis
Hashim, Maulood, Rasheed, Fatak, Kabah et al., Controlled randomized clinical trial on using ivermectin with doxycycline for treating COVID-19 patients in Baghdad, Iraq, doi:10.1101/2020.10
Hellwig, A COVID-19 prophylaxis? Lower incidence associated with prophylactic administration of ivermectin, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.106248
Hill, Abdulamir, Ahmed, Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection
Holshue, Debolt, Lindquist, Lofy, Wiesman et al., First case of 2019 novel coronavirus in the United States, N Engl J Med
Inc, Biontech, In vitro studies demonstrate Pfizer and BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with key mutations present in U.K. and South African variants
Jabeen, Khader, Jabeen, A review on the antiparasitic drug ivermectin for various viral infections and possibilities of using it for novel severe acute respiratory syndrome coronavirus 2: New hope to treat coronavirus disease-2019, Asian J Pharm Clin Res
Jans, Wagstaff, Ivermectin as a broad-spectrum host-directed antiviral: The real deal?, Cells, doi:10.3390/cells9092100
Kalhor, Sadeghi, Abolhasani, Kalhor, Rahimi, Repurposing of the approved small molecule drugs in order to inhibit SARS-CoV-2ʼs protein and human ACE2 interaction through virtual screening approaches, J Biomol Struct Dyn, doi:10.1080/07391102.2020.1824816
Kanoh, Rubin, Mechanisms of action and clinical application of macrolides as immunomodulatory medications, Clin Microbiol Rev
Khater, Das, Repurposing ivermectin to inhibit the activity of SARS CoV-2 helicase: possible implications for COVID 19 therapeutics
Kory, Meduri, Iglesias, Varon, Berkowitz et al., Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19
Krolewiecki, Lifschitz, Moragas, Antiviral effect of high-dose ivermectin in adults with COVID-19: a pilot randomised, controlled, open label, multicentre trial
Kudoh, Azuma, Tamaoki, Takizawa, Nakata et al., Novel action of erythromycin and its derivatives
Kudoh, Azuma, Yamamoto, Izumi, Ando, Improvement of survival in patient with diffuse panbronchiolitis treated with low-dose erythromycin, Am J Respir Crit Care Med
Kunihiro, Kitasato, A placebo-controlled, randomized, double-blind study in COVID-19 patients with ivermectin; An investigator initiated trial
Labour, Welfare, Cabinet Order: To designate the new coronavirus infectious disease as the type of infectious disease under Article 34 of the Quarantine Law
Lawrie, Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance
Lee, Perl, Nair, Microvascular injury in the brains of patients with Covid-19, N Engl J Med, doi:10.1056/NEJMc2033369
Lehrer, Rheinstein, Ivermectin docks to the SARS-CoV-2 spike receptor-binding domain attached to ACE2, vivo
Mahmud, Clinical trial of ivermectin plus doxycycline for the treatment of COVId-19 infection
Maruta, He, PAK1-blockers: Potential therapeutics against COVID-19, Medicine in Drug Discovery, doi:10.1016/j.medidd.2020.100039
Mectizan, Program, Mectizan Expert Committee statement on potential efficacy of ivermectin on COVID-19
Moderna, emerging variants first identified in the U.K. and the Republic of South Africa
Mohan, Tiwari, Suri, Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial
Mondal, Quintili, Karamchandani, Bose, Thromboembolic disease in COVID-19 patients: A brief narrative review, J Intensive Care, doi:10.1186/s40560-020-00483-y
Morgenstern, Redondo, Leon, The use of compassionate ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center PuntaCana, rescue group, doi:10.1101/2020.10.29.20222505
Munster, Koopmans, Van Doremalen, Van Riel, De, A novel coronavirus emerging in China -Key questions for impact assessment, N Engl J Med, doi:10.1056/NEJMp2000929
Niaee, Gheibi, Namdar, Allami, Zolghadr et al., Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial, doi:10.21203/rs.3.rs-109670/v1
Okumus, Ivermectin for severe COVID-19 management
Olsen, Chen, Liu, Early introduction of severe acute respiratory syndrome coronavirus 2 into Europe, Emerg Infect Dis, doi:10.3201/eid2607.200359
Pena-Silva, Duffull, Steer, Jaramillo-Rincon, Gwee et al., Pharmacokinetic consideration on the repurposing of ivermectin fro treatment of COVID-19, Br J Clin Pharmacol, doi:10.1111/bcp.14476
Pharmaceutical, Ltd, Start of a Japanese clinical study of TAK-919, Modernaʼs COVID-19 vaccine candidate
Podder, Chowdhury, Sina, Haque, Outcome of ivermectin treated mild to moderate COVID-19 cases: a single-center, open-label, randomized controlled study, IMC J Med Sci
Puntmann, Carerj, Wieters, Outcomes of cardiovascular magnetic resonance imaging in patients recently recovered from coronavirus disease 2019 (COVID-19), JAMA Cardiol
Rahman, Iqbal, Islam, Niaz, Hussain et al., Comparison of viral clearance between ivermectin with doxycycline and hydroxychloroquine with azithromycin in COVID-19 patients, J Bangladesh Coll Phys Surg
Rajter, Sherman, Fatteh, Vogel, Sacks et al., Use of ivermectin is associated with lower mortality in hospitalized patients with coronavirus disease 2019. The ivermectin in COVID nineteen study, Chest
Rezai, Effectiveness of Ivermectin in the Treatment of Coronavirus Infection in Patients admitted to Educational Hospitals of Mazandaran in
Rubin, Baden, Morrissey, Campion, Medical journals and the 2019-nCoV outbreak, Editorials. N Eng J Med. online, doi:10.1056/NEJMe2001329
Scheim, From cold to killer: How SARS-CoV-2 evolved without hemagglutinin esterase to agglutinate, the clot blood cells in pulmonary and systemic microvasculature
Scheim, Ivermectin for COVID-19 treatment: clinical response at quasi-threshold doses via hypothesized alleviation of CD147-mediated vascular occlusion
Schmith, Zhou, Lohmer, The approved dose of ivermectin alone is not the ideal dose for the treatment of COVID-19, Clin Pharmacol Therap, doi:10.1002/cpt.1889
Schonegger, Gietl, Heinzle, Freudenschuss, Walder, Smell and taste disorders in COVID-19 patients: objective testing and magnetic resonance imaging in five cases, SN Comp Clin Med
Sharp, Corp, Merck statement on ivermectin use during the COVID-19 pandemic
Sharun, Dhama, Ivermectin, a new candidate therapeutic against SARS-CoV-2/ COVID-19, Ann Clin Microbiol Antimicrob, doi:10.1186/s12941-020-00368-w
Shouman, Use of ivermectin as a prophylactic option in asymptomatic family close contact for patient with COVID-19
Spoorthi, Sasank, Utility of ivermectin and doxycycline combination for the treatment of SARS-CoV-2, IAIM
Swargiary, Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies, doi:10.21203/rs.3.rs-73308/v1
Takizawa, Desaki, Ohtoshi, Erythromycin suppresses interleukin 6 expression by human bronchial epithelial cells: A potential mechanism of its anti-inflammatory action, Biochem Biophys Res Commun
Tamaoki, Isono, Sakai, Kanemura, Konno, Erythromycin inhibits Cl secretion across canine tracheal epithelial cells, Eur Respir J
Vora, Arora, Behera, Tripathy, White paper on ivermectin as a potent therapy for COVID-19, Indian J Tuberc
Wagstaff, Sivakumaran, Heaton, Harrich, Jans, Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus, Biochem J
Yamaoka, -01
Ōmura, A splendid gift from the earth: The origins and impact of the avermectins (Nobel Lecture), Angew Chem Int Ed
Ōmura, Crump, The life and times of ivermectin -a success story, Nat Rev Microbiol
Ōmura, Ivermectin: 25 years and still going strong, Int. J Antimicrob Agents
Ōmura, Tsuzuki, Sunazuka, Toyota, Takahashi et al., Gastrointestinal motor-stimulating activity of macrolide antibiotics and the structure-activity relationships, J Antibiot
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit